As a promising biomarker, human epididymis protein 4 (HE4) has been widely used for the early detection and differential diagnosis of ovarian cancer. This study evaluated the function of HE4 in the carcinogenesis and progression of ovarian cancer. An enzyme immunometric assay, used to detect HE4 in the serum of ovarian cancer patients, showed that the protein could discriminate between malignant and benign ovarian tumours with high specificity. An exogenous HE4 gene was transfected into ovarian cancer cell lines and an immortalized ovarian epithelial cell line. Compared with the controls, HE4 overexpression significantly promoted cell apoptosis and adhesion. Overexpression of HE4 also led to significant inhibition of cell proliferation, migration and invasiveness in vitro, as well as xenograft tumour formation in vivo. This is the first report to demonstrate the functional importance of HE4 in multiple cellular processes and indicates that HE4 may play a protective role in the progression of ovarian cancer.
JemalASiegelRWardE: Cancer statistics, 2009. CA Cancer J Clin2009; 59: 225–249.
2.
SuhKSParkSWCastroA: Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn2010; 10: 1069–1083.
3.
BastRCJr: Status of tumour markers in ovarian cancer screening. J Clin Oncol2003; 21 (10 suppl): 200S–205S.
4.
DuttaSWangFQFishmanDA: The dire need to develop a clinically validated screening 4 method for the detection of early-stage ovarian cancer. Biomark Med2010; 4: 437–439.
5.
KirchhoffCHabbenIIvellR: A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod1991; 45: 350–357.
6.
KirchhoffC: Molecular characterization of epididymal proteins. Rev Reprod1998; 3: 86–95.
7.
DrapkinRvon HorstenHHLinY: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res2005; 65: 2162–2169.
8.
GalganoMTHamptonGMFriersonHFJr: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol2006; 19: 847–853.
9.
LamyPJRoquesSVigliantiC: HE4, a novel marker for epithelial ovarian cancer: evaluation of analytical performances. Ann Biol Clin (Paris)2010; 68: 325–329 [in French, English abstract].
10.
HellströmIHeagertyPJSwisherEM: Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett2010; 296: 43–48.
11.
YamashitaSTokuishiKHashimotoT: Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol2011; 32: 265–271.
12.
BingleLCrossSSHighAS: WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res2006; 7: 61.
13.
MooreRGBrownAKMillerMC: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol2008; 110: 196–201.
14.
HegmansJPVeltmanJDFungET: Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol Cancer Res Treat2009; 8: 323–332.
MontagnanaMLippiGDaneseE: Usefulness of serum HE4 in endometriotic cysts. Br J Cancer2009; 101: 548.
19.
AnastasiEMarcheiGGViggianiV: HE4: A new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol2010; 31: 113–119.
20.
KöbelMKallogerSEBoydN: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med2008; 5: e232.
21.
BerryNBChoYMHarringtonMA: Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol2004; 92: 896–904.
22.
YurkovetskyZSkatesSLomakinA: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol2010; 28: 2159–2166.
23.
AndersonGLMcIntoshMWuL: Assessing lead time of selected ovarian cancer biomarkers: A nested case-control study. J Natl Cancer Inst2010; 102: 26–38.
24.
DongLChangXHYeX: The values of serum human epididymis secretory protein 4 and CA125 assay in the diagnosis of ovarian malignancy. Zhonghua Fu Chan Ke Za Zhi (China)2008; 43: 931–936 [in Chinese, English abstract].
25.
ChangXYeXDongL: Human epididymis protein 4 (HE4) as a serum tumor bio marker in patients with ovarian carcinoma. Int J Gynecol Cancer2011; 21: 852–858.
26.
LiuYYeXChengH: Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors. Zhonghua Fu Chan Ke Za Zhi2010; 45: 363–366 [in Chinese, English abstract].
27.
HellströmIRaycraftJLedbetterM Hayden: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res2003; 63: 3695–3700.
28.
MooreRGMcMeekinDSBrownAK: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol2009; 112: 40–46.
29.
Maines-BandieraSLKrukPAAuerspergN: Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol1992; 167: 729–735.
30.
ChenL, (ed): Diagnostic Gynecologic and Obstetric Pathology, 2nd edn.Beijing: People's Military Medical Press, 2010; pp 268–394.
31.
KakuTOgawaSKawanoY: Histological classification of ovarian cancer. Med Electron Microsc2003; 36: 9–17.
32.
MooreRGBrownAKMillerMC: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol2008; 108: 402–408.
33.
ClaussALiljaHLundwallA: The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun2005; 333: 383–389.
34.
BouchardDMorissetDBourbonnaisY: Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol2006; 7: 167–174.
35.
ClaussALiljaHLundwallA: A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J2002; 368: 233–242.
36.
BingleLSingletonVBingleCD: The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene2002; 21: 2768–2773.
37.
DevoogdtNRevetsHGhassabehGH: Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci2004; 1028: 380–389.
38.
HuYSunHDrakeJ: From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res2004; 64: 7748–7755.
39.
TianXShigemasaKHirataE: Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep2004; 12: 1001–1006.
40.
TaggartCCGreeneCMMcElvaneyNG: Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IκBα degradation without affecting phosphorylation or ubiquitination. J Biol Chem2002; 277: 33648–33653.
41.
SungJTurnerJMcCarthyS: Oncogene regulation of tumor suppressor genes in tumorigenesis. Carcinogenesis2005; 26: 487–494.
42.
LiYSarkarFH: Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr2002; 132: 3623–3631.
43.
LiangGGonzalesFAJonesPA: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res2002; 62: 961–966.
44.
WestinUNyströmMLjungcrantzI: The presence of elafin, SLPI, IL1-RA and STNFα RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm2002; 11: 7–12.
